سعر ليبيفيبرت 105 مجم 30 قرص 2025

Fenofibrate 105 mg oral tablets, a fibrate (PPAR-alpha agonist) lipid-modifying agent mainly used to lower triglycerides.

• Severe renal impairment, including patients receiving dialysis.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Active liver disease, including primary biliary cirrhosis and unexplained persistent liver function abnormalities.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Pre-existing gallbladder disease.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Nursing mothers.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to fenofibrate or fenofibric acid.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Hepatotoxicity, including serious drug-induced liver injury requiring transplantation and death, has been reported; monitor liver tests and discontinue if liver injury is suspected.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Myopathy and rhabdomyolysis; risk is increased in the elderly and in diabetes, renal insufficiency or hypothyroidism, and with concomitant statins or colchicine.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Reversible serum creatinine elevations; monitor renal function in patients with renal impairment or at risk.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Cholelithiasis (discontinue if gallstones are found), pancreatitis, haematological changes, hypersensitivity reactions (including severe cutaneous reactions), venous thromboembolism and paradoxical severe decreases in HDL-C.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Coumarin anticoagulants (e.g. warfarin)Potentiate anticoagulant effect (PT/INR prolongation); reduce anticoagulant dose and monitor PT/INR frequently.DailyMed (U.S. National Library of Medicine)
• Immunosuppressants (cyclosporine, tacrolimus)Risk of deterioration of renal function; weigh benefits and risks and use the lowest effective dose.DailyMed (U.S. National Library of Medicine)
• Bile acid binding resinsTake fenofibrate at least 1 hour before or 4 to 6 hours after the resin.DailyMed (U.S. National Library of Medicine)
• Colchicine; statinsIncreased risk of myopathy including rhabdomyolysis; use with caution.DailyMed (U.S. National Library of Medicine)

• Limited data in pregnant women are insufficient to determine a drug-associated risk; no embryo-fetal toxicity was seen in animal studies at clinically relevant doses.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Women should not breastfeed during treatment and for 5 days after the final dose (US TRICOR label).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Monitor liver tests, renal function in at-risk patients, PT/INR with coumarin anticoagulants, and blood counts during the first 12 months.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Fenofibrate: Active moiety fenofibric acid activates PPAR-alpha, increasing lipolysis and elimination of triglyceride-rich particles by activating lipoprotein lipase and reducing apoprotein C-III (US TRICOR label).